Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10157190 | 1.00 | IDO1 (0.42) | IDO1TDO2AOC3ACHETRPA1 | |
| SCHEMBL10159881 | 1.00 | IDO1 (0.42) | IDO1TDO2AOC3ACHETRPA1 | |
| SCHEMBL13804088 | 0.93 | CYP17A1 (0.44) | IDO1TDO2AOC3ACHETRPA1 | |
| SCHEMBL19262099 | 0.84 | AOC3 (0.39) | IDO1TDO2AOC3ACHETRPA1 | |
| SCHEMBL15087367 | 0.79 | AOC3 (0.44) | IDO1TDO2AOC3ACHETRPA1 | |
| SCHEMBL17086654 | 0.79 | AOC3 (0.44) | IDO1TDO2AOC3ACHETRPA1 | |
| SCHEMBL17086639 | 0.79 | AOC3 (0.44) | IDO1TDO2AOC3ACHETRPA1 | |
| SCHEMBL17086688 | 0.79 | AOC3 (0.44) | IDO1TDO2AOC3ACHETRPA1 | |
| SCHEMBL10157213 | 0.78 | IDO1 (0.42) | IDO1TDO2AOC3ACHETRPA1 | |
| SCHEMBL7267227 | 0.77 | IDO1 (0.43) | IDO1TDO2AOC3ACHEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12041848-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2024-07-16 | — | — | US | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| WO-2023165262-A1 | THIENO-NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| WO-2023165263-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| WO-2023154291-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230250071-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2023-08-10 | — | — | US | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-9023865-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| US-8268998-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110245252-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-7982033-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982033-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110117081-A1 | FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS | AEGERA THERAPEUTICS, INC. (CA) | 2011-05-19 | — | — | US | disclosed |
| US-20110117081-A1 | FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS | AEGERA THERAPEUTICS, INC. (CA) | 2011-05-19 | — | — | US | disclosed |
| US-20100081662-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
| US-20100081662-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | CNR2, CNR1, GPR18 | IDO1 2071/4885TDO2 2113/4885AOC3 3494/4885 |
| US-20100081662-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | IDO1 2239/4885TDO2 1035/4885AOC3 2802/4885 |
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | IDO1 952/4885TDO2 1732/4885AOC3 4369/4885 |
| US-20230250071-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | IDO1 352/4885TDO2 1899/4885AOC3 1592/4885 |
| US-12041848-B2 | Heterocyclic compound and organic light emitting element comprising same | CRY1, CRY2, NR2E3 | IDO1 1967/4885TDO2 790/4885AOC3 336/4885 |
| US-20110245252-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | IDO1 2239/4885TDO2 1035/4885AOC3 2802/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | IDO1 952/4885TDO2 1732/4885AOC3 4369/4885 |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | IDO1 3829/4885TDO2 4200/4885AOC3 2389/4885 |
| US-20110117081-A1 | FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS | BIRC5, BIRC7, BIRC2 | IDO1 410/4885TDO2 4315/4885AOC3 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.